Structural neuroimaging biomarkers for obsessive-compulsive disorder in the ENIGMA-OCD consortium: medication matters

No diagnostic biomarkers are available for obsessive-compulsive disorder (OCD). Here, we aimed to identify magnetic resonance imaging (MRI) biomarkers for OCD, using 46 data sets with 2304 OCD patients and 2068 healthy controls from the ENIGMA consortium. We performed machine learning analysis of re...

Descripción completa

Detalles Bibliográficos
Autores: Alonso, Pino, Calvo Escalona, Rosa, Lázaro García, Luisa, Martínez Zalacaín, Ignacio, Menchón Magriñá, José Manuel, Morer Liñán, Astrid, Pariente, Jose Carlos, Soriano Mas, Carles, ENIGMA-OCD working group
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/173974
Acceso en línea:https://hdl.handle.net/2445/173974
Access Level:acceso abierto
Palabra clave:Neurosi obsessiva
Marcadors bioquímics
Obsessive-compulsive disorder
Biochemical markers
id ES_cfec08f715ed4cc76b4db4aff3d5a99a
oai_identifier_str oai:diposit.ub.edu:2445/173974
network_acronym_str ES
network_name_str España
repository_id_str
spelling Structural neuroimaging biomarkers for obsessive-compulsive disorder in the ENIGMA-OCD consortium: medication mattersAlonso, PinoCalvo Escalona, RosaLázaro García, LuisaMartínez Zalacaín, IgnacioMenchón Magriñá, José ManuelMorer Liñán, AstridPariente, Jose CarlosSoriano Mas, CarlesENIGMA-OCD working groupNeurosi obsessivaMarcadors bioquímicsObsessive-compulsive disorderBiochemical markersNo diagnostic biomarkers are available for obsessive-compulsive disorder (OCD). Here, we aimed to identify magnetic resonance imaging (MRI) biomarkers for OCD, using 46 data sets with 2304 OCD patients and 2068 healthy controls from the ENIGMA consortium. We performed machine learning analysis of regional measures of cortical thickness, surface area and subcortical volume and tested classification performance using cross-validation. Classification performance for OCD vs. controls using the complete sample with different classifiers and cross-validation strategies was poor. When models were validated on data from other sites, model performance did not exceed chance-level. In contrast, fair classification performance was achieved when patients were grouped according to their medication status. These results indicate that medication use is associated with substantial differences in brain anatomy that are widely distributed, and indicate that clinical heterogeneity contributes to the poor performance of structural MRI as a disease marker.Springernature2020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/173974Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.1038/s41398-020-01013-yTranslational Psychiatry, 2020, Vol. 10, num. 342https://doi.org/10.1038/s41398-020-01013-yinfo:eu-repo/grantAgreement/EC/FP7/278948cc by (c) Alonso, Pino et al., 2020http://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1739742026-05-27T06:46:51Z
dc.title.none.fl_str_mv Structural neuroimaging biomarkers for obsessive-compulsive disorder in the ENIGMA-OCD consortium: medication matters
title Structural neuroimaging biomarkers for obsessive-compulsive disorder in the ENIGMA-OCD consortium: medication matters
spellingShingle Structural neuroimaging biomarkers for obsessive-compulsive disorder in the ENIGMA-OCD consortium: medication matters
Alonso, Pino
Neurosi obsessiva
Marcadors bioquímics
Obsessive-compulsive disorder
Biochemical markers
title_short Structural neuroimaging biomarkers for obsessive-compulsive disorder in the ENIGMA-OCD consortium: medication matters
title_full Structural neuroimaging biomarkers for obsessive-compulsive disorder in the ENIGMA-OCD consortium: medication matters
title_fullStr Structural neuroimaging biomarkers for obsessive-compulsive disorder in the ENIGMA-OCD consortium: medication matters
title_full_unstemmed Structural neuroimaging biomarkers for obsessive-compulsive disorder in the ENIGMA-OCD consortium: medication matters
title_sort Structural neuroimaging biomarkers for obsessive-compulsive disorder in the ENIGMA-OCD consortium: medication matters
dc.creator.none.fl_str_mv Alonso, Pino
Calvo Escalona, Rosa
Lázaro García, Luisa
Martínez Zalacaín, Ignacio
Menchón Magriñá, José Manuel
Morer Liñán, Astrid
Pariente, Jose Carlos
Soriano Mas, Carles
ENIGMA-OCD working group
author Alonso, Pino
author_facet Alonso, Pino
Calvo Escalona, Rosa
Lázaro García, Luisa
Martínez Zalacaín, Ignacio
Menchón Magriñá, José Manuel
Morer Liñán, Astrid
Pariente, Jose Carlos
Soriano Mas, Carles
ENIGMA-OCD working group
author_role author
author2 Calvo Escalona, Rosa
Lázaro García, Luisa
Martínez Zalacaín, Ignacio
Menchón Magriñá, José Manuel
Morer Liñán, Astrid
Pariente, Jose Carlos
Soriano Mas, Carles
ENIGMA-OCD working group
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Neurosi obsessiva
Marcadors bioquímics
Obsessive-compulsive disorder
Biochemical markers
topic Neurosi obsessiva
Marcadors bioquímics
Obsessive-compulsive disorder
Biochemical markers
description No diagnostic biomarkers are available for obsessive-compulsive disorder (OCD). Here, we aimed to identify magnetic resonance imaging (MRI) biomarkers for OCD, using 46 data sets with 2304 OCD patients and 2068 healthy controls from the ENIGMA consortium. We performed machine learning analysis of regional measures of cortical thickness, surface area and subcortical volume and tested classification performance using cross-validation. Classification performance for OCD vs. controls using the complete sample with different classifiers and cross-validation strategies was poor. When models were validated on data from other sites, model performance did not exceed chance-level. In contrast, fair classification performance was achieved when patients were grouped according to their medication status. These results indicate that medication use is associated with substantial differences in brain anatomy that are widely distributed, and indicate that clinical heterogeneity contributes to the poor performance of structural MRI as a disease marker.
publishDate 2020
dc.date.none.fl_str_mv 2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/173974
url https://hdl.handle.net/2445/173974
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1038/s41398-020-01013-y
Translational Psychiatry, 2020, Vol. 10, num. 342
https://doi.org/10.1038/s41398-020-01013-y
info:eu-repo/grantAgreement/EC/FP7/278948
dc.rights.none.fl_str_mv cc by (c) Alonso, Pino et al., 2020
http://creativecommons.org/licenses/by/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by (c) Alonso, Pino et al., 2020
http://creativecommons.org/licenses/by/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Springernature
publisher.none.fl_str_mv Springernature
dc.source.none.fl_str_mv Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869420127154339840
score 15,300724

Similares en LA Referencia